RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
109 hedge funds and large institutions have $842M invested in RAPT Therapeutics in 2021 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 35 increasing their positions, 23 reducing their positions, and 9 closing their positions.
344% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 9
80% more capital invested
Capital invested by funds: $468M → $842M (+$374M)
52% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 23
40% more funds holding
Funds holding: 78 → 109 (+31)
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
0.74% more ownership
Funds ownership: 10.61% → 11.34% (+0.74%)
2% less call options, than puts
Call options by funds: $53.3M | Put options by funds: $54.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.7M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$13.3M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$12.8M |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$9.83M |
| 5 |
VA
VR Adviser
New York
|
+$9.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KXA
KPCB XV Associates
Menlo Park,
California
|
-$15.2M |
| 2 |
ROTUOC
Regents of the University of California
Oakland,
California
|
-$5.08M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.45M |
| 4 |
Millennium Management
New York
|
-$1.84M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$1.55M |
RAPT Hedge Fund Activity: Q2 2021 in Review
109 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2021, worth a combined $842M — up 80% from $468M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new RAPT positions and 9 closed out — a net gain of 31 holders — while 35 added to existing stakes and 23 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $23.7M. The largest seller was KPCB XV Associates, cutting an estimated $15.2M.
- 109 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2021, up from 78 in Q1 2021.
- Funds reported $842M of RAPT Therapeutics stock for Q2 2021, up 80% quarter-over-quarter.
- 40 funds opened new RAPT Therapeutics positions in Q2 2021 and 9 closed out, a net change of +31 holders.
- The largest RAPT Therapeutics buyer in Q2 2021 was T. Rowe Price Associates, an estimated $23.7M added.
- The largest RAPT Therapeutics seller in Q2 2021 was KPCB XV Associates, an estimated $15.2M sold.
Based on aggregated 13F filings for Q2 2021.